APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumor Necrosis Factor Inhibitors Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Tumor Necrosis Factor Inhibitors Drug Industry Research Report 2026

22 December 2025147 pages

Choose your research edition.

Industry ResearchTumor Necrosis Factor Inhibitors Drug Industry Research Report 2026147 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumor Necrosis Factor Inhibitors Drug Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Tumor Necrosis Factor Inhibitors Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumor Necrosis Factor Inhibitors Drug Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumor Necrosis Factor Inhibitors Drug Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Tumor Necrosis Factor Inhibitors Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Tumor Necrosis Factor Inhibitors Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Tumor Necrosis Factor Inhibitors Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Tumor Necrosis Factor Inhibitors Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Tumor Necrosis Factor Inhibitors Drug include Sandoz, Novartis, GlaxoSmithKline, Zydus Cadila, UCB, Tsumura, Toyama Chemical, Simcere Pharmaceutical and Shanghai Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Tumor Necrosis Factor Inhibitors Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tumor Necrosis Factor Inhibitors Drug Market by Company

Sandoz

Novartis

GlaxoSmithKline

Zydus Cadila

UCB

Tsumura

Toyama Chemical

Simcere Pharmaceutical

Shanghai Pharmaceuticals

Shanghai CP Guojian Pharmaceutical

Sanofi-Aventis

Samsung Bioepis

Reliance Life Sciences

PROBIOMED

Momenta Pharmaceuticals

MedImmune

LG Life Sciences

LEO Pharma

Janssen Biotech

Intas Pharmaceuticals

HanAll Biopharma

EPIRUS Biopharmaceuticals

Dexa Medica

Delenex Therapeutics

Celltrion

Celgene Corporation

CASI Pharmaceuticals

Bionovis

AryoGen Biopharma

Apogenix

Tumor Necrosis Factor Inhibitors Drug Segment by Type

Enbrel (Etanercept)

Simponi (Golimumab)

Cimzia (Certolizumab Pegol)

Remicade (Infliximab)

Otezla (Apremilast)

Humira ( Adalimumab)

Tumor Necrosis Factor Inhibitors Drug Segment by Application

Clinic

Hospital

Others

Tumor Necrosis Factor Inhibitors Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Inhibitors Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Inhibitors Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Inhibitors Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Tumor Necrosis Factor Inhibitors Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Tumor Necrosis Factor Inhibitors Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Tumor Necrosis Factor Inhibitors Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Tumor Necrosis Factor Inhibitors Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Tumor Necrosis Factor Inhibitors Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Tumor Necrosis Factor Inhibitors Drug Revenue of Manufacturers (2021-2026) Table 9. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Tumor Necrosis Factor Inhibitors Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Tumor Necrosis Factor Inhibitors Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Product Type & Application Table 14. Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Tumor Necrosis Factor Inhibitors Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sandoz Company Information Table 19. Sandoz Business Overview Table 20. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Sandoz Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 22. Sandoz Recent Developments Table 23. Novartis Company Information Table 24. Novartis Business Overview Table 25. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Novartis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 27. Novartis Recent Developments Table 28. GlaxoSmithKline Company Information Table 29. GlaxoSmithKline Business Overview Table 30. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 32. GlaxoSmithKline Recent Developments Table 33. Zydus Cadila Company Information Table 34. Zydus Cadila Business Overview Table 35. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 37. Zydus Cadila Recent Developments Table 38. UCB Company Information Table 39. UCB Business Overview Table 40. UCB Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. UCB Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 42. UCB Recent Developments Table 43. Tsumura Company Information Table 44. Tsumura Business Overview Table 45. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Tsumura Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 47. Tsumura Recent Developments Table 48. Toyama Chemical Company Information Table 49. Toyama Chemical Business Overview Table 50. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 52. Toyama Chemical Recent Developments Table 53. Simcere Pharmaceutical Company Information Table 54. Simcere Pharmaceutical Business Overview Table 55. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 57. Simcere Pharmaceutical Recent Developments Table 58. Shanghai Pharmaceuticals Company Information Table 59. Shanghai Pharmaceuticals Business Overview Table 60. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 62. Shanghai Pharmaceuticals Recent Developments Table 63. Shanghai CP Guojian Pharmaceutical Company Information Table 64. Shanghai CP Guojian Pharmaceutical Business Overview Table 65. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 67. Shanghai CP Guojian Pharmaceutical Recent Developments Table 68. Sanofi-Aventis Company Information Table 69. Sanofi-Aventis Business Overview Table 70. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 72. Sanofi-Aventis Recent Developments Table 73. Samsung Bioepis Company Information Table 74. Samsung Bioepis Business Overview Table 75. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 77. Samsung Bioepis Recent Developments Table 78. Reliance Life Sciences Company Information Table 79. Reliance Life Sciences Business Overview Table 80. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 82. Reliance Life Sciences Recent Developments Table 83. PROBIOMED Company Information Table 84. PROBIOMED Business Overview Table 85. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 87. PROBIOMED Recent Developments Table 88. Momenta Pharmaceuticals Company Information Table 89. Momenta Pharmaceuticals Business Overview Table 90. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 92. Momenta Pharmaceuticals Recent Developments Table 93. MedImmune Company Information Table 94. MedImmune Business Overview Table 95. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. MedImmune Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 97. MedImmune Recent Developments Table 98. LG Life Sciences Company Information Table 99. LG Life Sciences Business Overview Table 100. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 102. LG Life Sciences Recent Developments Table 103. LEO Pharma Company Information Table 104. LEO Pharma Business Overview Table 105. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 107. LEO Pharma Recent Developments Table 108. Janssen Biotech Company Information Table 109. Janssen Biotech Business Overview Table 110. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 112. Janssen Biotech Recent Developments Table 113. Intas Pharmaceuticals Company Information Table 114. Intas Pharmaceuticals Business Overview Table 115. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 117. Intas Pharmaceuticals Recent Developments Table 118. HanAll Biopharma Company Information Table 119. HanAll Biopharma Business Overview Table 120. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 122. HanAll Biopharma Recent Developments Table 123. EPIRUS Biopharmaceuticals Company Information Table 124. EPIRUS Biopharmaceuticals Business Overview Table 125. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 127. EPIRUS Biopharmaceuticals Recent Developments Table 128. Dexa Medica Company Information Table 129. Dexa Medica Business Overview Table 130. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 132. Dexa Medica Recent Developments Table 133. Delenex Therapeutics Company Information Table 134. Delenex Therapeutics Business Overview Table 135. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 137. Delenex Therapeutics Recent Developments Table 138. Celltrion Company Information Table 139. Celltrion Business Overview Table 140. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Celltrion Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 142. Celltrion Recent Developments Table 143. Celgene Corporation Company Information Table 144. Celgene Corporation Business Overview Table 145. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 147. Celgene Corporation Recent Developments Table 148. CASI Pharmaceuticals Company Information Table 149. CASI Pharmaceuticals Business Overview Table 150. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 151. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 152. CASI Pharmaceuticals Recent Developments Table 153. Bionovis Company Information Table 154. Bionovis Business Overview Table 155. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 156. Bionovis Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 157. Bionovis Recent Developments Table 158. AryoGen Biopharma Company Information Table 159. AryoGen Biopharma Business Overview Table 160. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 161. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 162. AryoGen Biopharma Recent Developments Table 163. Apogenix Company Information Table 164. Apogenix Business Overview Table 165. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 166. Apogenix Tumor Necrosis Factor Inhibitors Drug Product Portfolio Table 167. Apogenix Recent Developments Table 168. Global Tumor Necrosis Factor Inhibitors Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 169. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2021-2026) & (k units) Table 170. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2021-2026) Table 171. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2027-2032) & (k units) Table 172. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2027-2032) Table 173. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2021-2026) & (US$ Million) Table 174. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2021-2026) Table 175. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2027-2032) & (US$ Million) Table 176. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2027-2032) Table 177. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 178. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 179. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 180. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2026) & (US$ Million) Table 181. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2027-2032) & (US$ Million) Table 182. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 183. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 184. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 185. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2026) & (US$ Million) Table 186. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2027-2032) & (US$ Million) Table 187. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 188. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 189. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 190. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2026) & (US$ Million) Table 191. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2027-2032) & (US$ Million) Table 192. South America Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 193. South America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 194. South America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 195. South America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2026) & (US$ Million) Table 196. South America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2027-2032) & (US$ Million) Table 197. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 198. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2026) & (k units) Table 199. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2027-2032) & (k units) Table 200. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2026) & (US$ Million) Table 201. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2027-2032) & (US$ Million) Table 202. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2026) & (k units) Table 203. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2027-2032) & (k units) Table 204. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2021-2026) Table 205. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2027-2032) Table 206. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2021-2026) & (US$ Million) Table 207. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2027-2032) & (US$ Million) Table 208. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2021-2026) Table 209. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2027-2032) Table 210. Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2021-2026) & (US$/unit) Table 211. Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2027-2032) & (US$/unit) Table 212. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2026) & (k units) Table 213. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2027-2032) & (k units) Table 214. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2021-2026) Table 215. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2027-2032) Table 216. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2021-2026) & (US$ Million) Table 217. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2027-2032) & (US$ Million) Table 218. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2021-2026) Table 219. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2027-2032) Table 220. Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2021-2026) & (US$/unit) Table 221. Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2027-2032) & (US$/unit) Table 222. Key Raw Materials Table 223. Raw Materials Key Suppliers Table 224. Tumor Necrosis Factor Inhibitors Drug Distributors List Table 225. Tumor Necrosis Factor Inhibitors Drug Customers List Table 226. Tumor Necrosis Factor Inhibitors Drug Industry Trends Table 227. Tumor Necrosis Factor Inhibitors Drug Industry Drivers Table 228. Tumor Necrosis Factor Inhibitors Drug Industry Restraints Table 229. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Tumor Necrosis Factor Inhibitors Drug Product Image Figure 5. Global Tumor Necrosis Factor Inhibitors Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Tumor Necrosis Factor Inhibitors Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Tumor Necrosis Factor Inhibitors Drug Sales (2021-2032) & (k units) Figure 8. Global Tumor Necrosis Factor Inhibitors Drug Average Price (US$/unit) & (2021-2032) Figure 9. Enbrel (Etanercept) Product Image Figure 10. Simponi (Golimumab) Product Image Figure 11. Cimzia (Certolizumab Pegol) Product Image Figure 12. Remicade (Infliximab) Product Image Figure 13. Otezla (Apremilast) Product Image Figure 14. Humira ( Adalimumab) Product Image Figure 15. Clinic Product Image Figure 16. Hospital Product Image Figure 17. Others Product Image Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Tumor Necrosis Factor Inhibitors Drug Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Tumor Necrosis Factor Inhibitors Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region in 2025 Figure 24. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region in 2025 Figure 25. North America Tumor Necrosis Factor Inhibitors Drug Market Size by Country in 2025 Figure 26. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 27. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2021-2032) Figure 28. United States Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Country in 2025 Figure 32. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 33. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2021-2032) Figure 34. Germany Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Country in 2025 Figure 45. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2021-2032) Figure 47. China Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Tumor Necrosis Factor Inhibitors Drug Market Size by Country in 2025 Figure 56. South America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 57. South America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2021-2032) Figure 58. Brazil Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Colombia Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Country in 2025 Figure 63. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Country (2021-2032) Figure 65. Egypt Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2021-2032) Figure 71. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2021-2032) Figure 72. Global Tumor Necrosis Factor Inhibitors Drug Price (US$/unit) by Type (2021-2032) Figure 73. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2021-2032) Figure 74. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2021-2032) Figure 75. Global Tumor Necrosis Factor Inhibitors Drug Price (US$/unit) by Application (2021-2032) Figure 76. Tumor Necrosis Factor Inhibitors Drug Value Chain Figure 77. Tumor Necrosis Factor Inhibitors Drug Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Tumor Necrosis Factor Inhibitors Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Enbrel (Etanercept)
  • Simponi (Golimumab)
  • Cimzia (Certolizumab Pegol)
  • Remicade (Infliximab)
  • Otezla (Apremilast)
  • Humira ( Adalimumab)
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Sandoz
  • Novartis
  • GlaxoSmithKline
  • Zydus Cadila
  • UCB
  • Tsumura
  • Toyama Chemical
  • Simcere Pharmaceutical
  • Shanghai Pharmaceuticals
  • Shanghai CP Guojian Pharmaceutical
  • Sanofi-Aventis
  • Samsung Bioepis
  • Reliance Life Sciences
  • PROBIOMED
  • Momenta Pharmaceuticals
  • MedImmune
  • LG Life Sciences
  • LEO Pharma
  • Janssen Biotech
  • Intas Pharmaceuticals
  • HanAll Biopharma
  • EPIRUS Biopharmaceuticals
  • Dexa Medica
  • Delenex Therapeutics
  • Celltrion
  • Celgene Corporation
  • CASI Pharmaceuticals
  • Bionovis
  • AryoGen Biopharma
  • Apogenix

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size (2021-2032)
  4. 2.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales (2021-2032)
  5. 2.2.3 Global Tumor Necrosis Factor Inhibitors Drug Market Average Price (2021-2032)
  6. 2.3 Tumor Necrosis Factor Inhibitors Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Enbrel (Etanercept)
  9. 2.3.3 Simponi (Golimumab)
  10. 2.3.4 Cimzia (Certolizumab Pegol)
  11. 2.3.5 Remicade (Infliximab)
  12. 2.3.6 Otezla (Apremilast)
  13. 2.3.7 Humira ( Adalimumab)
  14. 2.4 Tumor Necrosis Factor Inhibitors Drug by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Clinic
  17. 2.4.3 Hospital
  18. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Tumor Necrosis Factor Inhibitors Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Tumor Necrosis Factor Inhibitors Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Tumor Necrosis Factor Inhibitors Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Tumor Necrosis Factor Inhibitors Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Tumor Necrosis Factor Inhibitors Drug, Established Date
  9. 3.9 Global Tumor Necrosis Factor Inhibitors Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sandoz
  2. 4.1.1 Sandoz Company Information
  3. 4.1.2 Sandoz Business Overview
  4. 4.1.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sandoz Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  6. 4.1.5 Sandoz Recent Developments
  7. 4.2 Novartis
  8. 4.2.1 Novartis Company Information
  9. 4.2.2 Novartis Business Overview
  10. 4.2.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Novartis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  12. 4.2.5 Novartis Recent Developments
  13. 4.3 GlaxoSmithKline
  14. 4.3.1 GlaxoSmithKline Company Information
  15. 4.3.2 GlaxoSmithKline Business Overview
  16. 4.3.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  18. 4.3.5 GlaxoSmithKline Recent Developments
  19. 4.4 Zydus Cadila
  20. 4.4.1 Zydus Cadila Company Information
  21. 4.4.2 Zydus Cadila Business Overview
  22. 4.4.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  24. 4.4.5 Zydus Cadila Recent Developments
  25. 4.5 UCB
  26. 4.5.1 UCB Company Information
  27. 4.5.2 UCB Business Overview
  28. 4.5.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 UCB Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  30. 4.5.5 UCB Recent Developments
  31. 4.6 Tsumura
  32. 4.6.1 Tsumura Company Information
  33. 4.6.2 Tsumura Business Overview
  34. 4.6.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Tsumura Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  36. 4.6.5 Tsumura Recent Developments
  37. 4.7 Toyama Chemical
  38. 4.7.1 Toyama Chemical Company Information
  39. 4.7.2 Toyama Chemical Business Overview
  40. 4.7.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  42. 4.7.5 Toyama Chemical Recent Developments
  43. 4.8 Simcere Pharmaceutical
  44. 4.8.1 Simcere Pharmaceutical Company Information
  45. 4.8.2 Simcere Pharmaceutical Business Overview
  46. 4.8.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  48. 4.8.5 Simcere Pharmaceutical Recent Developments
  49. 4.9 Shanghai Pharmaceuticals
  50. 4.9.1 Shanghai Pharmaceuticals Company Information
  51. 4.9.2 Shanghai Pharmaceuticals Business Overview
  52. 4.9.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  54. 4.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 4.10 Shanghai CP Guojian Pharmaceutical
  56. 4.10.1 Shanghai CP Guojian Pharmaceutical Company Information
  57. 4.10.2 Shanghai CP Guojian Pharmaceutical Business Overview
  58. 4.10.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  60. 4.10.5 Shanghai CP Guojian Pharmaceutical Recent Developments
  61. 4.11 Sanofi-Aventis
  62. 4.11.1 Sanofi-Aventis Company Information
  63. 4.11.2 Sanofi-Aventis Business Overview
  64. 4.11.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  66. 4.11.5 Sanofi-Aventis Recent Developments
  67. 4.12 Samsung Bioepis
  68. 4.12.1 Samsung Bioepis Company Information
  69. 4.12.2 Samsung Bioepis Business Overview
  70. 4.12.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  72. 4.12.5 Samsung Bioepis Recent Developments
  73. 4.13 Reliance Life Sciences
  74. 4.13.1 Reliance Life Sciences Company Information
  75. 4.13.2 Reliance Life Sciences Business Overview
  76. 4.13.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  78. 4.13.5 Reliance Life Sciences Recent Developments
  79. 4.14 PROBIOMED
  80. 4.14.1 PROBIOMED Company Information
  81. 4.14.2 PROBIOMED Business Overview
  82. 4.14.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  84. 4.14.5 PROBIOMED Recent Developments
  85. 4.15 Momenta Pharmaceuticals
  86. 4.15.1 Momenta Pharmaceuticals Company Information
  87. 4.15.2 Momenta Pharmaceuticals Business Overview
  88. 4.15.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  90. 4.15.5 Momenta Pharmaceuticals Recent Developments
  91. 4.16 MedImmune
  92. 4.16.1 MedImmune Company Information
  93. 4.16.2 MedImmune Business Overview
  94. 4.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 MedImmune Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  96. 4.16.5 MedImmune Recent Developments
  97. 4.17 LG Life Sciences
  98. 4.17.1 LG Life Sciences Company Information
  99. 4.17.2 LG Life Sciences Business Overview
  100. 4.17.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  102. 4.17.5 LG Life Sciences Recent Developments
  103. 4.18 LEO Pharma
  104. 4.18.1 LEO Pharma Company Information
  105. 4.18.2 LEO Pharma Business Overview
  106. 4.18.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  108. 4.18.5 LEO Pharma Recent Developments
  109. 4.19 Janssen Biotech
  110. 4.19.1 Janssen Biotech Company Information
  111. 4.19.2 Janssen Biotech Business Overview
  112. 4.19.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  114. 4.19.5 Janssen Biotech Recent Developments
  115. 4.20 Intas Pharmaceuticals
  116. 4.20.1 Intas Pharmaceuticals Company Information
  117. 4.20.2 Intas Pharmaceuticals Business Overview
  118. 4.20.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  120. 4.20.5 Intas Pharmaceuticals Recent Developments
  121. 4.21 HanAll Biopharma
  122. 4.21.1 HanAll Biopharma Company Information
  123. 4.21.2 HanAll Biopharma Business Overview
  124. 4.21.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  126. 4.21.5 HanAll Biopharma Recent Developments
  127. 4.22 EPIRUS Biopharmaceuticals
  128. 4.22.1 EPIRUS Biopharmaceuticals Company Information
  129. 4.22.2 EPIRUS Biopharmaceuticals Business Overview
  130. 4.22.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  132. 4.22.5 EPIRUS Biopharmaceuticals Recent Developments
  133. 4.23 Dexa Medica
  134. 4.23.1 Dexa Medica Company Information
  135. 4.23.2 Dexa Medica Business Overview
  136. 4.23.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  138. 4.23.5 Dexa Medica Recent Developments
  139. 4.24 Delenex Therapeutics
  140. 4.24.1 Delenex Therapeutics Company Information
  141. 4.24.2 Delenex Therapeutics Business Overview
  142. 4.24.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  144. 4.24.5 Delenex Therapeutics Recent Developments
  145. 4.25 Celltrion
  146. 4.25.1 Celltrion Company Information
  147. 4.25.2 Celltrion Business Overview
  148. 4.25.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  149. 4.25.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  150. 4.25.5 Celltrion Recent Developments
  151. 4.26 Celgene Corporation
  152. 4.26.1 Celgene Corporation Company Information
  153. 4.26.2 Celgene Corporation Business Overview
  154. 4.26.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  155. 4.26.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  156. 4.26.5 Celgene Corporation Recent Developments
  157. 4.27 CASI Pharmaceuticals
  158. 4.27.1 CASI Pharmaceuticals Company Information
  159. 4.27.2 CASI Pharmaceuticals Business Overview
  160. 4.27.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  161. 4.27.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  162. 4.27.5 CASI Pharmaceuticals Recent Developments
  163. 4.28 Bionovis
  164. 4.28.1 Bionovis Company Information
  165. 4.28.2 Bionovis Business Overview
  166. 4.28.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  167. 4.28.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  168. 4.28.5 Bionovis Recent Developments
  169. 4.29 AryoGen Biopharma
  170. 4.29.1 AryoGen Biopharma Company Information
  171. 4.29.2 AryoGen Biopharma Business Overview
  172. 4.29.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  173. 4.29.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  174. 4.29.5 AryoGen Biopharma Recent Developments
  175. 4.30 Apogenix
  176. 4.30.1 Apogenix Company Information
  177. 4.30.2 Apogenix Business Overview
  178. 4.30.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2021-2026)
  179. 4.30.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Product Portfolio
  180. 4.30.5 Apogenix Recent Developments
5 Global Tumor Necrosis Factor Inhibitors Drug Market Scenario by Region
  1. 5.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region: 2027-2032
  5. 5.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2027-2032
  8. 5.4 North America Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Country
  9. 5.4.1 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Country
  41. 5.7.1 South America Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Tumor Necrosis Factor Inhibitors Drug Value Chain Analysis
  2. 8.1.1 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Tumor Necrosis Factor Inhibitors Drug Production Mode & Process
  5. 8.2 Tumor Necrosis Factor Inhibitors Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Tumor Necrosis Factor Inhibitors Drug Distributors
  8. 8.2.3 Tumor Necrosis Factor Inhibitors Drug Customers
9 Global Tumor Necrosis Factor Inhibitors Drug Analyzing Market Dynamics
  1. 9.1 Tumor Necrosis Factor Inhibitors Drug Industry Trends
  2. 9.2 Tumor Necrosis Factor Inhibitors Drug Industry Drivers
  3. 9.3 Tumor Necrosis Factor Inhibitors Drug Industry Opportunities and Challenges
  4. 9.4 Tumor Necrosis Factor Inhibitors Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst